Professional Advisory Services Inc. boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 64.7% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 59,511 shares of the medical research company’s stock after purchasing an additional 23,369 shares during the period. Thermo Fisher Scientific accounts for 3.8% of Professional Advisory Services Inc.’s holdings, making the stock its 5th biggest holding. Professional Advisory Services Inc.’s holdings in Thermo Fisher Scientific were worth $28,864,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently modified their holdings of the company. Financial Management Network Inc. lifted its position in Thermo Fisher Scientific by 3.7% in the 3rd quarter. Financial Management Network Inc. now owns 511 shares of the medical research company’s stock valued at $248,000 after purchasing an additional 18 shares during the last quarter. Elevation Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 35.1% in the third quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 20 shares during the period. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the last quarter. S.A. Mason LLC boosted its position in shares of Thermo Fisher Scientific by 7.0% during the third quarter. S.A. Mason LLC now owns 319 shares of the medical research company’s stock worth $155,000 after buying an additional 21 shares during the period. Finally, Lafayette Investments Inc. raised its stake in Thermo Fisher Scientific by 2.4% during the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock valued at $376,000 after acquiring an additional 22 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.
Thermo Fisher Scientific Trading Down 0.9%
Thermo Fisher Scientific stock opened at $619.16 on Tuesday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $629.87. The firm’s 50 day moving average price is $587.17 and its two-hundred day moving average price is $526.57. The firm has a market cap of $232.62 billion, a price-to-earnings ratio of 35.77, a price-to-earnings-growth ratio of 4.07 and a beta of 0.91. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50.
Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.
Thermo Fisher Scientific Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.
Insider Buying and Selling
In other news, COO Michel Lagarde sold 32,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $583.39, for a total value of $18,668,480.00. Following the transaction, the chief operating officer directly owned 65,480 shares of the company’s stock, valued at $38,200,377.20. This trade represents a 32.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Frederick M. Lowery sold 6,913 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the completion of the sale, the executive vice president owned 14,367 shares of the company’s stock, valued at approximately $8,586,868.56. This trade represents a 32.49% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 149,271 shares of company stock valued at $86,507,282. Company insiders own 0.33% of the company’s stock.
Analysts Set New Price Targets
A number of research analysts have recently commented on TMO shares. Morgan Stanley raised their price target on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, January 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Friday, January 9th. Redburn Partners set a $580.00 price target on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $625.47.
Get Our Latest Stock Analysis on Thermo Fisher Scientific
About Thermo Fisher Scientific
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
See Also
- Five stocks we like better than Thermo Fisher Scientific
- Wall Street Alert: Buy AES
- Your Bank Account Is No Longer Safe
- Refund From 1933: Trump’s Reset May Create Instant Wealth
- Trump’s AI Secret: 100X Faster Than Nvidia
- Trump Did WHAT??
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
